Clin Endosc.  2011 Sep;44(1):33-37.

Dual Therapy Trial Using Esomeprazole and Amoxicillin as Third-line Rescue Therapy for Helicobacter pylori Infection

• Park HK
• Lee DH
• Suh S
• Seo PJ
• Kim N
• Jeong SH
• Kim JW
• Hwang JH
• Park YS
• Lee SH
• Shin CM

Abstract

BACKGROUND/AIMS
The purpose of this study was to evaluate the efficacy and tolerability of dual therapy consisting of esomeprazole and amoxicillin as a rescue therapy for Helicobacter pylori infection.
METHODS
From December 2009 to August 2010, 21 patients who experienced two consecutive eradication failures were included. They received esomeprazole (40 mg, b.i.d.) and amoxicillin (1,000 mg, b.i.d.) for 14 days as a third eradication regimen. Compliance and side effects were determined from an interview. H. pylori status was evaluated using the 13C urea breath test at least 6 weeks after treatment.
RESULTS
The mean age of the patients was 59 years and included 52% males. Indications for treatment were functional dyspepsia (61.9%), peptic ulcer disease (28.6%), and gastric adenoma (9.5%). H. pylori was eradicated in 14 of 21 (66.7%) patients. Minor side effects were reported in three of the 21 patients (14.3%). These side effects consisted mainly of nausea and epigastric discomfort.
CONCLUSIONS
A 2-week course of dual therapy failed to show satisfactory results in third-line H. pylori eradication, but it was very safe and tolerable. Therefore, dual therapy constitutes an encouraging empirical strategy for the elderly and infirm patients with multiple previous eradication failures.

Keyword

Helicobacter pylori; Therapy; Proton pump inhibitor; Amoxicillin

MeSH Terms

Adenoma
Aged
Amoxicillin
Breath Tests
Compliance
Dyspepsia
Esomeprazole Sodium
Helicobacter
Helicobacter pylori
Humans
Male
Nausea
Peptic Ulcer
Urea
Amoxicillin
Esomeprazole Sodium
Urea

Reference

1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002; 347:1175–1186. PMID: 12374879.

2. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007; 56:772–781. PMID: 17170018.

3. Choi YS, Cheon JH, Lee JY, et al. The trend of eradication rates of first-line triple therapy for Helicobacter pylori infection: single center experience for recent eight years. Korean J Gastroenterol. 2006; 48:156–161. PMID: 17047430.

4. Na HS, Hong SJ, Yoon HJ, et al. Eradication rate of first-line and second-line therapy for Helicobacter pylori infection, and reinfection rate after successful eradication. Korean J Gastroenterol. 2007; 50:170–175. PMID: 17885282.

5. Yoon H, Kim N, Lee BH, et al. Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate. Helicobacter. 2009; 14:77–85. PMID: 19751431.

6. Perri F, Festa V, Clemente R, et al. Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol. 2001; 96:58–62. PMID: 11197288.

7. Miehlke S, Kirsch C, Schneider-Brachert W, et al. A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter. 2003; 8:310–319. PMID: 12950604.

8. Miehlke S, Hansky K, Schneider-Brachert W, et al. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Aliment Pharmacol Ther. 2006; 24:395–403. PMID: 16842467.

9. Yim JY, Kim N, Choi SH, et al. Seroprevalence of Helicobacter pylori in South Korea. Helicobacter. 2007; 12:333–340. PMID: 17669107.

10. Gisbert JP, Pajares JM. Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther. 2002; 16:1047–1057. PMID: 12030945.

11. Sànchez JE, Sàenz NG, Rincón MR, Martín IT, Sánchez EG, Martínez MJ. Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones. J Antimicrob Chemother. 2000; 46:283–285. PMID: 10933654.

12. Tanaka M, Isogai E, Isogai H, et al. Synergic effect of quinolone antibacterial agents and proton pump inhibitors on Helicobacter pylori. J Antimicrob Chemother. 2002; 49:1039–1040. PMID: 12039901.

13. Kim JM. Antibiotic resistance of Helicobacter pylori isolated from Korean patients. Korean J Gastroenterol. 2006; 47:337–349. PMID: 16714875.

14. Gisbert JP, Calvet X, Bujanda L, Marcos S, Gisbert JL, Pajares JM. 'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter. 2003; 8:90–94. PMID: 12662375.

15. Perri F, Festa V, Clemente R, Quitadamo M, Andriulli A. Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther. 2000; 14:311–316. PMID: 10735924.

16. Heep M, Beck D, Bayerdörffer E, Lehn N. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother. 1999; 43:1497–1499. PMID: 10348780.

17. Canducci F, Ojetti V, Pola P, Gasbarrini G, Gasbarrini A. Rifabutin-based Helicobacter pylori eradication 'rescue therapy'. Aliment Pharmacol Ther. 2001; 15:143. PMID: 11136288.

18. Bayerdörffer E, Miehlke S, Mannes GA, et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology. 1995; 108:1412–1417. PMID: 7729633.

19. Miehlke S, Mannes GA, Lehn N, Hele C, Stolte M, Bayerdörffer E. An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively. Aliment Pharmacol Ther. 1997; 11:323–329. PMID: 9146770.

20. Lamouliatte H, Cayla R, Zerbib F, et al. Dual therapy using a double dose of lansoprazole with amoxicillin versus triple therapy using a double dose of lansoprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori infection: results of a prospective randomized open study. Am J Gastroenterol. 1998; 93:1531–1534. PMID: 9732938.

21. Westblom TU, Duriex DE. Enhancement of antibiotic concentrations in gastric mucosa by H2-receptor antagonist. Implications for treatment of Helicobacter pylori infections. Dig Dis Sci. 1991; 36:25–28. PMID: 1985000.

22. Kim JJ, Reddy R, Lee M, et al. Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J Antimicrob Chemother. 2001; 47:459–461. PMID: 11266421.

23. Cammarota G, Martino A, Pirozzi G, et al. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. Aliment Pharmacol Ther. 2004; 19:789–795. PMID: 15043520.

24. Nam TM, Lee DH, Kang KP, et al. Clinical factors that potentially affect the treatment outcome of Helicobacter pylori eradication therapy with using a standard triple regimen in peptic ulcer patients. Korean J Gastrointest Endosc. 2008; 36:200–205.

25. Mégraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004; 53:1374–1384. PMID: 15306603.

26. Vergara M, Vallve M, Gisbert JP, Calvet X. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003; 18:647–654. PMID: 12969092.

27. Keum B, Lee SW, Kim SY, et al. Comparison of Helicobacter pylori eradication rate according to different PPI-based triple therapy: omeprazole, rabeprazole, esomeprazole and lansoprazole. Korean J Gastroenterol. 2005; 46:433–439. PMID: 16371717.

28. de Boer WA, Tytgat GN. Regular review: treatment of Helicobacter pylori infection. BMJ. 2000; 320:31–34. PMID: 10617524.

29. Zullo A, Hassan C, Lorenzetti R, Winn S, Morini S. A clinical practice viewpoint: to culture or not to culture Helicobacter pylori. Dig Liver Dis. 2003; 35:357–361. PMID: 12846409.

30. Guslandi M. Review article: alternative antibacterial agents for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2001; 15:1543–1547. PMID: 11563992.

31. Gomollón F, Sicilia B, Ducóns JA, Sierra E, Revillo MJ, Ferrero M. Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients. Aliment Pharmacol Ther. 2000; 14:1335–1338. PMID: 11012479.